


PHARMACEUTICAL 2023

## Hepion Pharmaceuticals Inc. Rank 181 of 446









PHARMACEUTICAL 2023



## Hepion Pharmaceuticals Inc. Rank 181 of 446

The relative strengths and weaknesses of Hepion Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Hepion Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 80% points. The greatest weakness of Hepion Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is 123%, being 80% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	56,496
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,886
Liabilities, Non-Current	0
Other Assets	3,667
Other Compr. Net Income	-90
Other Expenses	-1,003
Other Liabilities	2,503
Other Net Income	415
Other Revenues	0
Property and Equipment	82
Research and Development	33,269
Selling, General and Administrative Expense	10,348

Output Variable	Value in 1000 USD
Assets	60,244
Liabilities	10,389
Expenses	42,615
Revenues	0
Stockholders Equity	49,856
Net Income	-42,200
Comprehensive Net Income	-42,245
Economic Capital Ratio	123%

